Trapped inside a body that no longer works, unable to speak, move or, eventually, breathe. People with motor neurone disease (MND) know this is how their life will end, and with no treatment or cure available, it is a terrifying fate. Tofersen (brand name Qalsody) is an investigational drug developed by the company Biogen to … Read more
It’s been another busy year at Motor Neurone Disease NZ as we continue to evolve as an organisation, and work even harder to ensure we offer the best, and most appropriate, support that we can. With Christmas fast approaching, we would like to reflect on how privileged we feel to be able to walk alongside … Read more
The future of MND treatment in New Zealand: Best practice recommendations and beyond Wednesday 6 September, 20237pm – 8pm Comprehensive, multidisciplinary care is the current gold standard for treating MND. Motor Neurone Disease NZ recently facilitated the production of best practice guidelines for the care of people living with motor neurone disease. Developed over … Read more
The inaugural webinar in the newly developed MND New Zealand Community Forum series went successfully, with an impressive turnout and high engagement during the Q&A session. The webinar also saw the announcement of the publication of the NZ-based Best Practice Recommendations for the Care of People with MND. “As a early stage slow progressing MND … Read more
A new set of clinical guidelines for the management and care of individuals with MND has been published today, 8 November 2022. Developed over a number of years by a working group of New Zealand MND clinicians and funded by MND New Zealand, this first-ever New Zealand based best practice recommendations (BPRs) represent what specialists … Read more